Data Shows VisionGate’s 3D Imaging Platform Accurately Detects Lung Cancer in Sputum

free biotech news

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VisionGate, Inc., a company developing a revolutionary non-invasive test for the early detection of lung cancer, today reported clinical data showing that its automated 3D cell imaging platform, the Cell-CT™, can detect lung cancer in sputum samples with high sensitivity and specificity. The data was presented at the International Association for the Study of Lung Cancer (IASLC) 15th World Conference on Lung Cancer.

Hey, check out all the engineering jobs. Post your resume today!

MORE ON THIS TOPIC